Related Experiment Video
Updated: Aug 9, 2026

Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
(-)Deprenyl in the treatment of decompensated Parkinson's disease
Abstract:
Two main forms of declining motor performance are evident in Parkinson's disease: response fluctuations and "loss of benefit", i.e., the progression of the disease without "on-off" symptoms. (-)Deprenyl has a favourable beneficial effect in reducing the mild forms of response fluctuations. The addition of (-)deprenyl in such patients to the continuing substitution therapy prevents the development of more severe "on-off" manifestations. In severely disabled patients with irregular response swings or permanent akinesia the use of (-)deprenyl as an adjuvant drug cannot modify anymore the course of the disease.
Related Concept Videos
Parkinson's Disease: Overview
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Alzheimer's Disease: Treatment
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Parkinson Disease l: Introduction
Parkinson Disease ll: Pathophysiology

